Form 4: MariMed Inc. Insider Trading Activity

Timothy Shaw, Chief Operating Officer of MariMed Inc., reported transactions involving common stock and restricted stock units.

Summary

• Timothy Shaw, Chief Operating Officer of MariMed Inc., filed a Form 4 detailing transactions on April 2, 2026.
• He acquired 9,982 shares of common stock upon the vesting of Restricted Stock Units (RSUs) with a transaction code 'M'.
• Additionally, 3,459 shares were withheld by the issuer to cover tax obligations related to RSU vesting, with a transaction code 'F'.
• Following these transactions, Shaw beneficially owns 9,357,700 shares directly.
• He also holds 2,000,000 shares indirectly through the Shaw Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, reflecting routine insider equity transactions and compensation management rather than significant strategic or financial events.

Positives

• Acquisition of 9,982 shares of common stock through RSU vesting indicates continued equity participation.
• The company is managing tax withholding obligations efficiently in relation to RSU vesting.

Negatives

• 3,459 shares were withheld by the issuer to satisfy tax obligations, representing a reduction in the net shares received by the reporting person.

Future Outlook

The filing indicates future vesting of RSUs on October 2, 2026, and April 2, 2027, which will result in further acquisition of common stock by the reporting person.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and provide transparency into executive compensation and equity holdings within the cannabis industry.

Related Party Transactions

• The Shaw Family Trust holds 2,000,000 shares indirectly. The reporting person's spouse is the trustee, and the shares are for the benefit of the reporting person's children. The reporting person disclaims beneficial ownership of these securities.

Stakeholder Impact

• Shareholders gain insight into executive equity compensation and potential future share dilution from RSU vesting.
• Employees may view RSU vesting as a positive indicator of management's long-term commitment and alignment with company performance.

Next Steps

• Vesting of remaining RSUs on October 2, 2026.
• Vesting of remaining RSUs on April 2, 2027.

Key Dates

Keywords

MariMed Inc., MRMD, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Common Stock, Beneficial Ownership, Timothy Shaw, Chief Operating Officer